A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

Investigational New Drugs

Volumn 24, Issue 5, 2006, Pages 441-446

  Ajani, J A ^a   Safran, H ^b   Bokemeyer, C ^c,d   Shah, M A ^e   Lenz, H J ^f   Van Cutsem, E ^g   Burris III, H A ^h   Lebwohl, D ^a   Mullaney, B ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Memorial Sloan Kettering Cancer Center ^*

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g SARAH CANNON RESEARCH INSTITUTE   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IXABEPILONE; TAXANE DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BONE PAIN; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DIARRHEA; DRUG ACTIVITY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ELECTROCORTICOGRAPHY; ESOPHAGITIS; ESOPHAGUS CARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HISTOLOGY; HUMAN; HUMAN TISSUE; INFORMED CONSENT; LIVER TOXICITY; LOWER ESOPHAGUS SPHINCTER; MALE; METASTASIS; MULTICENTER STUDY; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUTROPENIA; NEUTROPHILIA; ODYNOPHAGIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN MANIFESTATION; SKIN TOXICITY; STOMACH ADENOCARCINOMA; STOMATITIS; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; DISEASE PROGRESSION; EPOTHILONES; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PERIPHERAL NERVOUS SYSTEM DISEASES; STOMACH NEOPLASMS; TAXOIDS;

EID: 33745052354     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-7304-8     Document Type: Article

References (14)

1. Bollag DM, McQueney PA, Zhu J, et al (1995) Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 55:2325-2333
2. Sepp-Lorenzino L, Balog A, Su DS, et al (1999) The microtubule- stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cells. Prostate Cancer Prostatic Dis 2:41-52
3. Newman RA, Yang J, Raymond M, et al (2001) Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 48:319-326
4. Galsky MD, Small EJ, Oh WK, et al (2005) Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in paitents with progressive castrate metastatic prostate cancer. J Clin Oncol 23:1439-1446
5. Low JA, Wedam SB, Brufsky A, et al (2005) Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2736
6. Thomas E, Tabernero J, Fornier M, et al (2003) A phase II study of the epothilone B analog BMS-247550 in patients (pts) with taxane-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 22:p. 8 (abstract 30)
7. Roche HH, Cure H, Bunnell C, et al (2003) A phase II study of epothilone analog BMS-247550 in patients (pts) with metastatic (MBC) breast cancer previously treated with an anthracycline. Proc Am Soc Clin Oncol 22:p. 18 (abstract 69)
8. Vansteenkiste JF, Breton J-L, Sandler A, et al (2003) A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with non-small cell lung cancer (NSCLC) who have failed first-line platinum-based chemotherapy. Proc Am Soc Clin Oncol 22: 626 (abstract 2519)
9. Zhuang SH, Menefee M, Kotz H, et al (2004) A phase II clinical trial of BMS-247550 (ixabepilone), a microtubule-stabilizing agent in renal cell cancer, J Clin Oncol 22 (abstract 4550)
10. Whitehead RP, McCoy SA, Rivkin SE, et al (2004) A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: A Southwest Oncology Group Study. J Clin Oncol 22(abstract 4012)
11. Lee FY, Borzilleri R, Fairchild CR, et al (2001) BMS-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 7:1429-1437
12. WHO Handbook of Reporting Results of Cancer Treatment, Geneva, 1979
13. Therasse PA, Arbuck SU, Eisenhauer EL, et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92:205-216
14. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10